Role of prostaglandins in the antimyoclonic action of clonazepam.
Possible involvement of prostaglandins (PG) in the antimyoclonic action of clonazepam was examined in the p,p'-DDT-animal model of myoclonus. PG synthesis inhibitors and the PG antagonist polyphloretin phosphate (PPP) counteracted the antimyoclonic action of clonazepam in mice. PGE2 reduced DDT-induced myoclonus; this effect was blocked by PPP. Another antimyoclonic drug combination, L-5-hydroxytryptophan plus chlorimipramine, was not blocked by PPP or indomethacin. The antimyoclonic action of clonazepam may be mediated by enhancement of PG synthesis.
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002997:Clomipramine / Q000494:pharmacology; D002998:Clonazepam / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D051379:Mice; D009207:Myoclonus / Q000139:chemically induced / Q000188:drug therapy*; D011121:Polyphloretin Phosphate / Q000494:pharmacology; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011453:Prostaglandins / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology
D001570:Benzodiazepinones; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D012701:Serotonin; D002998:Clonazepam; D011121:Polyphloretin Phosphate; D002997:Clomipramine; D007213:Indomethacin